Antares Pharma Inc. (ATRS)

3.48 +0.18 (+5.455%)

IEX Real-Time Price

9:30:58 AM EST.

NASDAQ Capital Market : Healthcare

Prev Close 3.3

Price Open 3.21

Volume: 344,828

Avg Volume: 1.09M

Market Cap: 547.88M

P/E Ratio -29

52 Wk Range 1.58-4.09



ATRS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
141.25M
6.37M
13.67
4.51%

2018-07-13
140.64M
6.26M
8.04
4.45%

2018-06-29
140.64M
6.21M
6.39
4.42%

2018-06-15
139.03M
6.21M
7.32
4.47%




ATRS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-08
Q1 2018
N/A
-0.03 (4)
-0.04
-0.01

2018-03-13
Q4 2017
N/A
-0.03 (5)
-0.04
-0.01

2017-11-07
Q3 2017
BTO
-0.03 (6)
-0.04
-0.01

2017-08-08
Q2 2017
BTO
-0.03 (6)
-0.04
-0.01

News

Antares Pharma announces FDA approval of generic EpiPen utilizing VIBEX Auto Injector (2018-08-17 07:05 SeekingAlpha)

Antares Pharma (NASDAQ: ATRS ) announces that the FDA has approved Teva Pharmaceutical Industries' epinephrine auto injector drug-device combination product indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and …

 


Statistics

Shares Outstanding: 157.44M

Top 15 Institution Percent: 37.70

Price To Sales: 9.44

Price To Book: 20.25

Revenue: 15.05M

Gross Profit: 6.53M

Cash: 37.41M

Debt: N/A

Return On Assets: -25.30

Return On Equity: -61.23

Profit Margin: -37.59

Price History

Beta: 0.19

50-day Moving Avg: 2.78

200-day Moving Avg: 2.33

YTD Change: 59.42

5-day Change: 13.99

1-month Change: 22.22

3-month Change: 28.40

6-month Change: 38.08

1-year Change: 9.27

Revenue Per Share: 0.00

Revenue Per Employee: 135607.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Antares Pharma Inc.

Exchange: NASDAQ Capital Market

Industry: Medical Instruments & Equipment

Sector: Healthcare

Website: http://www.antarespharma.com

Antares Pharma Inc is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies including novel, pressure-assisted injectors.